Combined cytokine therapy for sustained HIV remission
联合细胞因子疗法可持续缓解艾滋病毒
基本信息
- 批准号:10573329
- 负责人:
- 金额:$ 102.14万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-03-17 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AddressAdjuvantAnimal EuthanasiaAntiviral ResponseB-LymphocytesBLR1 geneBloodCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCell physiologyCellsChronicClinicCombined Modality TherapyComplexDNADNA/MVA vaccineDataDisease remissionGoalsHIVHIV InfectionsHIV/AIDSHelper-Inducer T-LymphocyteHomingHumanImmuneImmunityImmunotherapeutic agentIn VitroInfectionInterferon Type IIInterleukin-12Interleukin-15Interleukin-2InterruptionKnowledgeLymphoidLymphoid TissueMacacaMacaca mulattaModelingMorbidity - disease rateNatural Killer CellsPlasmaProductionProliferatingRNARoleSIVSIV VaccinesSafetyStructure of germinal center of lymph nodeT cell responseT-LymphocyteT-Lymphocyte SubsetsTNF geneTNFSF5 geneTestingTherapeuticTissuesTranslatingVaccinatedVaccinationVaccine TherapyViralViral reservoirViremiaVirus ReplicationWorkantiretroviral therapyantiviral immunitychemokine receptorcytokinecytokine therapycytotoxicimprovedin vivomortalitynovelnovel therapeuticsresponserestorationsafety testingsecondary lymphoid organsimian human immunodeficiency virus
项目摘要
Abstract
The overall goal of this proposal is to evaluate the safety and therapeutic potential of cytokine therapy and vaccination to
restore/enhance function of anti-viral immunity that will lead to sustained viral remission following anti-retroviral therapy
(ART) interruption against HIV using the SIV/Rhesus macaque (RM) model. Dysfunctional anti-HIV immunity and
persistence of viral reservoirs represent two major obstacles that must be addressed to achieve sustained viral remission in
the absence of ART. ART is highly effective in controlling virus replication but does not significantly improve T cell
function and reduce viral reservoirs. It is clear that anti-viral CD8 T cells are critical for the control of HIV/SIV replication.
Similarly, recent studies have highlighted the role of NK cells in controlling HIV/SIV infections. The majority of HIV
replication occurs in secondary lymphoid organs and a significant fraction of viral reservoirs during ART are concentrated
in T follicular helper cells (Tfh) that reside in B cell follicles and germinal centers (GC). However, B cell follicles are
largely devoid of anti-viral CD8 T cells and NK cells during chronic HIV/SIV infection. Thus, novel therapies that
restore/enhance function of both anti-viral CD8 T cells and NK cells, and promote follicular homing of these cells will
significantly enhance clearance of viral reservoirs within lymphoid tissues there by contribute to sustained viral remission
following analytical ART interruption (ATI). Our preliminary data demonstrated that combination of IL-12 plus IL-15/IL-
15Ra treatment markedly enhances the magnitude, cytokine production and cytotoxic potential of SIV-specific CD8+ T and
NK cells that was markedly superior to either cytokine treatment in vitro. In addition, combination cytokine treatment during
chronic SHIV infection was safe and resulted in expansion of anti-viral CD8 T cells and NK cells with follicular homing
potential that was associated with viral control. Interestingly, the combination cytokine therapy, unlike IL-15 monotherapy,
did not induce proliferation of CD4 T cells both in vitro and in vivo. Given these highly encouraging results, here we propose
to comprehensively test the effects of IL-15 and IL-12 either alone or in combination on different T and NK cell subsets
during chronic SIV infection and ART (Aim 1), and investigate how these changes influence viral reservoirs under ART
and viral control after ART interruption (Aim 2). In addition, we will combine the optimal cytokine therapy with vaccination
to further enhance the magnitude and breadth of SIV-specific CD4 and CD8 T cell responses that we hope will further
improve the therapeutic benefit (Aim 3). These studies will advance our knowledge about how IL-15 and IL-12 cytokines
differentially influence the function of different subsets of T and NK cells during chronic SIV infection and ART, and what
immune mechanisms induced by cytokine therapy and vaccination contribute to control of chronic SIV/HIV infections.
抽象的
该提案的总体目标是评估细胞因子疗法和疫苗接种的安全性和治疗潜力
恢复/增强抗病毒免疫功能,从而导致抗逆转录病毒治疗后病毒持续缓解
(ART) 使用 SIV/恒河猴 (RM) 模型阻断 HIV。抗 HIV 免疫功能失调和
病毒储存库的持续存在是实现持续病毒缓解必须解决的两个主要障碍
缺乏艺术。 ART在控制病毒复制方面非常有效,但并不能显着改善T细胞
发挥作用并减少病毒储存库。很明显,抗病毒 CD8 T 细胞对于控制 HIV/SIV 复制至关重要。
同样,最近的研究强调了 NK 细胞在控制 HIV/SIV 感染中的作用。大多数艾滋病毒
复制发生在次级淋巴器官,并且 ART 期间病毒库的很大一部分被浓缩
存在于 B 细胞滤泡和生发中心 (GC) 中的滤泡辅助 T 细胞 (Tfh) 中。然而,B 细胞滤泡
在慢性 HIV/SIV 感染期间,很大程度上缺乏抗病毒 CD8 T 细胞和 NK 细胞。因此,新疗法
恢复/增强抗病毒 CD8 T 细胞和 NK 细胞的功能,并促进这些细胞的滤泡归巢
显着增强淋巴组织内病毒库的清除,从而有助于持续的病毒缓解
分析 ART 中断 (ATI) 后。我们的初步数据表明,IL-12 加 IL-15/IL-
15Ra 治疗显着增强了 SIV 特异性 CD8+ T 的强度、细胞因子的产生和细胞毒性潜力
NK 细胞在体外明显优于任一细胞因子治疗。此外,联合细胞因子治疗
慢性 SHIV 感染是安全的,并导致抗病毒 CD8 T 细胞和 NK 细胞随滤泡归巢而扩增
与病毒控制相关的潜力。有趣的是,联合细胞因子疗法与 IL-15 单一疗法不同,
在体外和体内均不诱导CD4 T细胞增殖。鉴于这些非常令人鼓舞的结果,我们在此建议
全面测试 IL-15 和 IL-12 单独或组合对不同 T 和 NK 细胞亚群的影响
在慢性 SIV 感染和 ART 期间(目标 1),并研究这些变化如何影响 ART 下的病毒库
ART 中断后的病毒控制(目标 2)。此外,我们将最佳的细胞因子治疗与疫苗接种结合起来
进一步增强 SIV 特异性 CD4 和 CD8 T 细胞反应的程度和广度,我们希望这将进一步
提高治疗效果(目标 3)。这些研究将增进我们对 IL-15 和 IL-12 细胞因子如何发挥作用的了解
在慢性 SIV 感染和 ART 期间,不同亚群的 T 细胞和 NK 细胞的功能有不同的影响,以及什么
细胞因子治疗和疫苗接种诱导的免疫机制有助于控制慢性 SIV/HIV 感染。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rama Rao Amara其他文献
Rama Rao Amara的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rama Rao Amara', 18)}}的其他基金
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection
预防和根除 SIV/SHIV 感染的 B 和 T 细胞生物学
- 批准号:
10462362 - 财政年份:2022
- 资助金额:
$ 102.14万 - 项目类别:
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection
预防和根除 SIV/SHIV 感染的 B 和 T 细胞生物学
- 批准号:
10618319 - 财政年份:2022
- 资助金额:
$ 102.14万 - 项目类别:
Correlates of protective immunity to HCV and rational vaccine design: Project 3
HCV 保护性免疫与合理疫苗设计的相关性:项目 3
- 批准号:
10393619 - 财政年份:2021
- 资助金额:
$ 102.14万 - 项目类别:
Correlates of protective immunity to HCV and rational vaccine design: Project 3
HCV 保护性免疫与合理疫苗设计的相关性:项目 3
- 批准号:
10205769 - 财政年份:2021
- 资助金额:
$ 102.14万 - 项目类别:
Correlates of protective immunity to HCV and rational vaccine design: Project 3
HCV 保护性免疫与合理疫苗设计的相关性:项目 3
- 批准号:
10608113 - 财政年份:2021
- 资助金额:
$ 102.14万 - 项目类别:
Combined cytokine therapy for sustained HIV remission
联合细胞因子疗法可持续缓解艾滋病毒
- 批准号:
10348184 - 财政年份:2020
- 资助金额:
$ 102.14万 - 项目类别:
Targeting PD-1 Pathway for Functional Cure of AIDS
靶向 PD-1 通路实现艾滋病功能性治愈
- 批准号:
10349439 - 财政年份:2019
- 资助金额:
$ 102.14万 - 项目类别:
MVA Prime/Novel Trimeric Cyclically Permuted Envelope Protein Boost Vaccines for HIV
MVA Prime/新型三聚体循环排列包膜蛋白增强 HIV 疫苗
- 批准号:
10449340 - 财政年份:2019
- 资助金额:
$ 102.14万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 102.14万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 102.14万 - 项目类别:
Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 102.14万 - 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 102.14万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 102.14万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 102.14万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 102.14万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 102.14万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 102.14万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 102.14万 - 项目类别: